Class III and Implantable Device Registration in Jordan

1. Key takeaways

Class III devices in Jordan face a double layer of additional requirements: first, depth requirements on the CE documentation — the EC declarations of conformity for Full Quality Assurance and for Design Examination must both be submitted; second, requirements on review intensity — the probability of on-site inspection and local sample submission is significantly higher than for the lower-risk classes. GRZAN’s conclusion is that the volume of document preparation for a Class III project is several times that of a Class I project, and the cycle should be planned at approximately 8 months (practical estimate). Both layers follow from the same fact: Class III products sustain or enter life-critical functions, so neither the evidence nor the scrutiny can be lightened.

• The second conclusion: implantable devices hold an exempt position under the 2025 new policy. Circular No. 54863/1/5 (9 October 2025) provides that Class IIb devices may be imported only after registration is completed, but implantable devices are not covered. This exemption reflects JFDA’s consideration of the clinical urgency of implantable devices.
• The third conclusion: the illustrative scope of Class III is clear — stents, intraocular lenses (IOL), defibrillators, pacemakers and HIV blood-donor screening. The common feature of these products is that they are implantable or life-sustaining, and that is what determines the intensity of the review. A manufacturer entering Jordan with any product on this list should budget Class III-level effort from the very first project meeting, regardless of how routine the product is in other markets.

2. Legal basis

Article numbers are subject to the Arabic originals published in the official gazette of Jordan and issued by JFDA; the amounts are the official fees listed in the JFDA fee schedule.

3. Expert insights

Insight 1: EC Full Quality Assurance and Design Examination are the dual-module route for EU Class III devices. Jordan requires both to be complete, which in essence requires the company to demonstrate that its quality system covers the entire production process and that the product design has undergone an independent examination by a notified body. When pulling together the CE documentation, a company holding only one of the two will be asked to supplement the other. Starting the Class III project before that gap is closed only moves the discovery to the review stage, where it costs far more time.

Insight 2: the implantable exemption stands in contrast to the high review intensity for Class III. The 2025 circular pushes Class IIb to a “registration precondition” position, yet exempts implantable devices. GRZAN’s understanding is this: implantable devices usually fall into Class III, whose registration pathway is already the strictest; the exemption arrangement prevents clinically urgent implantable devices from being cut off by the customs clearance restrictions. For manufacturers, the practical takeaway is that implantable Class III products keep their normal registration timeline even under the 2025 policy, while non-implantable Class IIb siblings of the same portfolio do not.

Insight 3: the probability of an on-site inspection correlates with production complexity. For first-time applications of Class III devices with complex production conditions, the probability of an on-site inspection being arranged is higher. Companies need to ensure in advance that the quality management system is operating effectively and that complete records are retained. An inspection that finds live, orderly records closes quickly; one that finds reconstructed records closes slowly and with questions.

Insight 4: GMP and site approval form an independent production-side gate. The 2011 GMP guidelines govern whole-process quality, and the site approval fee is 700 JOD. Class III projects should include the possibility of site approval in both the budget and the cycle. Treating it as a contingent line item, with its own 700 JOD and its own lead time, keeps the project budget honest when the requirement materialises.

Insight 5: the Class III cycle and the certificate validity need to be matched. The practical Class III cycle is approximately 8 months (practical estimate), while the remaining validity of certificates such as ISO 13485 and CE is recommended to be no less than 6 months (practical estimate). The combination means companies should start the project while the certificate validity is ample, and renew the certificates first where necessary.

4. Practical recommendations

• First check the completeness of the CE document modules. A Class III application must confirm that both the Full Quality Assurance and the Design Examination declarations of conformity are available.
• Plan the cycle at 8 months, and reserve a buffer for on-site inspection and local sample submission (practical estimate).
• Prepare the inspection-readiness materials early. Organise the records according to the seven stages of the GMP guidelines and ensure they can be retrieved at any time.
• Recheck the applicability of the 2025 circular for implantable products. Confirm whether the product falls within the implantable exemption; the exemption does not apply to non-implantable Class IIb products.

5. Verification checklist

• □ Confirm the EC Full Quality Assurance and Design Examination declarations of conformity are complete
• □ Build the project plan on an 8 month practical cycle (practical estimate)
• □ Prepare the inspection-readiness materials according to the seven stages of the GMP guidelines
• □ Confirm whether a site approval (700 JOD) needs to be applied for
• □ Check whether implantable products fall within the exemption arrangement of Circular No. 54863/1/5
• □ Check whether the remaining validity of the ISO 13485 and CE certificates covers the review period
• □ Verify the cited article numbers against the Arabic original of the official gazette
• □ Regulatory information verified as of 29 October 2026

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team manages JFDA registration applications, prepares reference-approval dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzan.com